Automated Blood Coagulation Analyzer CN-Series (CN-6000)

K250965 · Sysmex America, Inc. · JPA · Jun 2, 2025 · Hematology

Device Facts

• Record ID: K250965
• Device Name: Automated Blood Coagulation Analyzer CN-Series (CN-6000)
• Applicant: Sysmex America, Inc.
• Product Code: JPA · Hematology
• Decision Date: Jun 2, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.5425
• Device Class: Class 2

Intended Use

The CN-series (CN-6000) is a fully automated blood coagulation analyzer intended for in vitro diagnostic use in the clinical laboratory. The instrument analyzes citrated plasma samples (3.2% sodium citrate) collected from venous blood using clotting, chromogenic and immunoassay methods. The performance of this device has not been established in neonate and pediatric patient populations.

Device Story

Fully automated coagulation analyzer for clinical laboratories; processes citrated plasma samples via clotting, chromogenic, and immunoassay methods. Input: venous blood samples in 3.2% sodium citrate tubes. Operation: automated pipetting, dilution, and incubation at 37°C; uses LED light source for detection (absorbance at 340, 405, 575, 660, or 800 nm). Output: quantitative results displayed on Information Processing Unit (IPU) screen, printable, or transmittable to host computer. Used by laboratory technicians to support clinical decision-making regarding coagulation status. Benefits: provides standardized, high-throughput analysis of clotting factors and markers, aiding diagnosis and monitoring of hemostatic disorders.

Clinical Evidence

Bench testing only. Method comparison studies (CLSI EP09C) across three sites (N=847 for PT, N=813 for INR, N=638 for APTT, N=456 for Fibrinogen, N=450 for Antithrombin, N=395 for D-dimer) showed high correlation (r ≥ 0.993) with the predicate. Precision studies (CLSI EP05-A3) demonstrated within-device CVs generally < 3%. Linearity, interference, carryover, and limit of quantitation studies met all pre-established acceptance criteria. No clinical patient outcome data provided.

Technological Characteristics

Fully automated coagulation analyzer. Sensing: Optical (transmitted light absorbance at 340, 405, 575, 660, 800 nm). Energy: Electrical. Connectivity: IPU screen, external printer, host computer interface. Sampling: Normal and micro modes, automatic pipetting/dilution. Reagent cooling: 4-15°C. Software: Rule-based/algorithmic processing for coagulation parameters. Complies with IEC 60601-1-2, IEC 61326-1, IEC 62471, and ANSI AAMI IEC 62304.

Indications for Use

Indicated for in vitro diagnostic use in clinical laboratories to analyze citrated plasma samples (3.2% sodium citrate) from venous blood for coagulation studies (PT, PT INR, APTT, Fibrinogen, Antithrombin, D-dimer). Performance not established in neonate or pediatric populations.

Regulatory Classification

Identification

A multipurpose system for in vitro coagulation studies is a device consisting of one automated or semiautomated instrument and its associated reagents and controls. The system is used to perform a series of coagulation studies and coagulation factor assays.

Special Controls

*Classification.* Class II (special controls). A control intended for use with a multipurpose system for in vitro coagulation studies is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

Predicate Devices

• Sysmex Automated Blood Coagulation Analyzer CS-5100 (K150678)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD &amp; DRUG ADMINISTRATION

June 2, 2025

Sysmex America, Inc.
Esther John-Olotu
Regulatory Affairs Manager
577 Aptakisic Road
Lincolnshire, Illinois 60069

Re: K250965
Trade/Device Name: Automated Blood Coagulation Analyzer CN-Series (CN-6000)
Regulation Number: 21 CFR 864.5425
Regulation Name: Multipurpose System For In Vitro Coagulation Studies
Regulatory Class: Class II
Product Code: JPA
Dated: March 28, 2025
Received: March 31, 2025

Dear Esther John-Olotu:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

U.S. Food &amp; Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K250965 - Esther John-Olotu
Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}

K250965 - Esther John-Olotu
Page 3

Sincerely,

MIN WU-S

Min Wu, Ph.D.
Branch Chief
Division of Immunology and Hematology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K250965 | |
| Device Name Automated Blood Coagulation Analyzer CN-Series (CN-6000) | |
| Indications for Use (Describe) | |
| The CN-Series (CN-6000) is a fully automated coagulation analyzer intended for in vitro diagnostic use in the clinical laboratory. The instrument analyzes citrated plasma samples (3.2 % sodium citrate) collected from venous blood, using clotting, chromogenic and immunoassay methods. The performance of this device has not been established in neonate and pediatric patient populations | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92

The assigned 510(k) number is: K250965

Submitter’s name, address, telephone number, contact person, and date the summary was prepared:

Submitter’s Name: Sysmex America, Inc.
Submitter’s Address: 577 Aptakisic Road
Lincolnshire, IL 60069
Submitter’s Telephone: [phone]
Submitter’s Contact: Esther John-Olotu
Date 510(k) Summary Prepared: March 28, 2025

Name of the device, including the trade or proprietary name, the common or usual name, and the classification name:

Proprietary name: Automated Blood Coagulation Analyzer CN-Series (CN-6000)
Common name: Automated Blood Coagulation Analyzer
Regulation description: Coagulation Instrument
Regulation Section: 21 CFR 864.5425
Device Class: II
Product Code: JPA

Predicate Device and 510(k) number:
Sysmex Automated Blood Coagulation Analyzer CS-5100 K150678

Description of the Device:

The CN-Series (CN-6000) coagulation analyzer is an automated blood coagulation instrument which can analyze samples using clotting, chromogenic and immunoassay methods. Analysis results are displayed on the IPU (Information Processing Unit) screen. They can be printed on external printers or transmitted to a host computer.

Sold separately from the instrument are the associated reagents, controls, calibrators, and consumable materials. The subject of this 510(k) notification is the analyzer together with the reagent applications which perform the coagulation tests:

- Prothrombin Time (PT) seconds and PT INR with Dade® Innovin®
- Activated Partial Thromboplastin Time (APTT) with Dade® Actin® FSL
- Fibrinogen (Fbg) with Dade® Thrombin Reagent
- Antithrombin (AT) with INNOVANCE® Antithrombin
- D-dimer with INNOVANCE® D-Dimer.

510(k) Summary
Page 1 of 13
Classified as Confidential

{5}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

The analysis principles used on the instrument are reflected by the reagent application testing provided in this submission and are described in the table below. These reagents were selected to show the analytical technology of the instrument while also selecting commonly used applications in coagulation laboratories in the United States.

| Reagent | Application | Methodology |
| --- | --- | --- |
| Dade® Innovin® | PT, Prothrombin Time (seconds) | Clotting (extrinsic pathway) |
| | PT, Prothrombin Time (INR) | Clotting, calculated |
| Dade® Actin® FSL | APTT, Activated Partial Thromboplastin Time | Clotting (intrinsic pathway) |
| Dade® Thrombin Reagent | Fibrinogen quantitation | Clotting (common pathway) |
| INNOVANCE® Antithrombin | Antithrombin quantitation | Chromogenic |
| INNOVANCE® D-Dimer | D-dimer quantitation | Immunochemical |

The intended environment of use is a clinical laboratory. The instrument and reagent applications are not labeled for home use nor for patient use.

## Statement of Intended Use:

The CN-series (CN-6000) is a fully automated blood coagulation analyzer intended for in vitro diagnostic use in the clinical laboratory. The instrument analyzes citrated plasma samples (3.2% sodium citrate) collected from venous blood using clotting, chromogenic and immunoassay methods.

The performance of this device has not been established in neonate and pediatric patient populations.

## Summary of Substantial Equivalence:

The CN-6000 uses the same principles of operation as the CS-5100 in using venous blood samples collected in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.

The main similarities between the CN-6000 instrument and the CS-5100 are listed in the device comparison Table 1 and differences are in Table 2 below:

510(k) Summary
Classified as Confidential

{6}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

Table 1: Instrument Comparison – Similarities with Predicate Device

| Analyzer Component | Predicate Device
CS-5100 (K150678) | Proposed Device
CN-6000 |
| --- | --- | --- |
| Intended Use | The Sysmex CS-5100 is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.

For determination of:
• Prothrombin Time (PT) seconds and PT INR with Dade® Innovin®
• Activated Partial Thromboplastin Time (APTT) with Dade® Actin® FSL
• Fibrinogen (Fbg) with Dade® Thrombin Reagent
• Antithrombin (AT) with INNOVANCE® Antithrombin
• D-dimer with INNOVANCE® D-Dimer

The performance of this device has not been established in neonate and pediatric patient populations. | The CN-6000 is a fully automated coagulation analyzer intended for in vitro diagnostic use in the clinical laboratory. The instrument analyzes citrated plasma samples (3.2 % sodium citrate) collected from venous blood, using clotting, chromogenic and immunoassay methods.

The performance of this device has not been established in neonate and pediatric patient populations. |
| Sample type | Human plasma, 3.2% sodium citrate | Same |
| Application type | **Clotting Applications:**
• Prothrombin Time (PT) seconds and PT INR with Dade® Innovin®
• Activated Partial Thromboplastin Time (APTT) with Dade® Actin® FSL
• Fibrinogen (Clauss) with Dade® Thrombin Reagent | Same |
| | **Chromogenic Application:**
Antithrombin with INNOVANCE® Antithrombin | Same |
| | **Immunoassay Application:**
D-dimer with INNOVANCE® D-Dimer | Same |

510(k) Summary
Classified as Confidential

{7}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

| Analyzer Component | Predicate Device
CS-5100 (K150678) | Proposed Device
CN-6000 |
| --- | --- | --- |
| Operating Principle | Clotting/Chromogenic/Immunoassay:
Transmitted Light Detection (Absorbance) at 340, 405, 575, 660 or 800 nm. | Same |
| Specimen Processing | Automatic Pipetting and Dilution | Same |
| Random Access | Yes | Same |
| Liquid Level Sensing | Yes – Reagent and Sample | Same |
| Bar code reader | Reagent and Sample | Same |
| Sample Barcodes | ITF, NW-7 (CODABAR), CODE-39, JAN-13, JAN-8, CODE-128 and ISBT128 | Same |
| STAT testing | Yes | Same |
| Sampling Capabilities | Normal and Micro Mode | Same |
| Cap Piercing | Cap Piercer | Same |
| Temperature Control | Sample incubation well: 37°C ± 1.0°C | Same |
| Pipetting Capabilities | Reagent probe: 20 - 200 μL
Sample probe: 4 - 270 μL | Same |
| Reagent Mixing | Automatic | Same |

Table 2 - Instrument Comparison – Differences with Predicate Device

| Analyzer Component | Predicate Device
CS-5100 (K150678) | Proposed Device
CN-6000 |
| --- | --- | --- |
| Cleaning Solutions On-board External | • CA-CLEAN I | • CN-COAGWASHER |
| | • CA-CLEAN II
• Dade® Owren’s Buffer
• Water | Same |
| Light Source | Chromogenic & Immunochemical: Halogen Lamp | LED |

510(k) Summary
Page 4 of 13
Classified as Confidential

{8}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

| Analyzer Component | Predicate Device
CS-5100 (K150678) | Proposed Device
CN-6000 |
| --- | --- | --- |
| Probes | • 2 Sample probes
• 3 Reagent probes | • 2 Sample probes
• 2 Reagent probes |
| Reagent Cooling | • 10°C ± 2°C, when the ambient temperature is 20°C - 28°C.
• 4°C - 15°C, when the ambient temperature is 15°C - 20°C or 28-30 °C | • 4°C - 12°C, when the ambient temperature is 15°C - 28°C
• 4°C - 15°C, when the ambient temperature is 28°C - 30°C |
| Sampler | • 10 sample racks can be set simultaneously | • 5 sample racks can be set simultaneously |

There are minor differences between the analyzers such as rinse and buffer solutions, light source, probes and reagent cooling. These differences do not impact the safety and performance of CN-6000.

## Summary of Performance Testing:

A series of studies were performed that evaluated traditional laboratory performance characteristics. A summary of each study follows:

## Method comparison:

Method comparison studies designed according to EP09C, 3rd edition CLSI Guideline were conducted at three clinical sites. Normal, abnormal samples, and samples at the medical decision levels were enrolled in order to adequately capture full spectrum of the analytical measuring interval (AMI). Samples were measured on both the predicate device (Sysmex® CS-5100) and the investigational device, CN-Series (CN-6000). Results were compared by Passing-Bablok regression analysis as well as Bland-Altman analysis. Results from each assay met the pre-established acceptance criteria. The following table shows a summary of Passing-Bablok regression analysis.

| Application (AMI) | Site A | Site B | Site C | Total Combined Sites |
| --- | --- | --- | --- | --- |
| Prothrombin Time with Dade® Innovin® (8.7 – 90.0 seconds) | N = 490
y = 1.012x – 0.134
r = 1.000 | N = 168
y = 1.000x
r = 0.999 | N = 189
y = 1.020x – 0.206
r = 0.997 | N = 847
y = 1.010x – 0.100
r = 0.999 |
| Prothrombin Time (INR) with Dade® Innovin® (0.93 – 8.00 INR) | N = 472
y = 1.013x – 0.012
r = 1.000 | N = 163
y = 1.000x
r = 0.999 | N = 178
y = 1.024x – 0.023
r = 0.996 | N = 813
y = 1.010x – 0.010
r = 0.999 |

510(k) Summary
Page 5 of 13
Classified as Confidential

{9}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

| Application (AMI) | Site A | Site B | Site C | Total Combined Sites |
| --- | --- | --- | --- | --- |
| Activated Partial Thromboplastin Time with Dade® Actin® FSL (20.0 – 139.0) seconds) | N = 401
y = 1.000x – 0.100
r = 0.997 | N = 126
y = 0.961x + 1.093
r = 0.998 | N = 111
y = 0.988x + 0.290
r = 0.994 | N = 638
y = 0.993x + 0.088
r = 0.996 |
| Fibrinogen quantitation with Dade® Thrombin Reagent (50 – 860 mg/dL) | N = 225
y = 1.067x + 4.517
r = 0.996 | N = 121
y = 1.015x – 9.987
r = 0.998 | N = 110
y = 1.077x – 11.731
r = 0.995 | N = 456
y = 1.062x – 4.092
r = 0.993 |
| Antithrombin quantitation with INNOVANCE® Antithrombin (9.0 – 128.0% of norm) | N = 221
y = 0.949x + 1.364
r = 0.997 | N = 115
y = 0.988x – 2.119
r = 0.998 | N = 114
y = 1.028x – 1.879
r = 0.997 | N = 450
y = 0.984x – 0.998
r = 0.995 |
| D-dimer quantitation with INNOVANCE® D-Dimer (0.19 – 35.20 mg/L FEU) | N = 194
y = 0.976x – 0.006
r = 0.998 | N = 101
y = 0.897x + 0.030
r = 0.999 | N = 100
y = 1.015x – 0.005
r = 0.998 | N = 395
y = 0.959x + 0.007
r = 0.997 |

Precision:

Precision studies were conducted over twenty days, two runs per day, and two replicates per run for a total of eighty data points per assay. The study was conducted in accordance with recommendations of CLSI EP05-A3 using commercial QC materials and plasma pools reflecting medical decision levels. The precision data are summarized in the table below.

| | Precision within-site | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | | Repeatability | | Within-Device/Lab Precision | |
| | | Mean | SD [assay unit] | CV (%) | SD [assay unit] | Within Device/Lab CV (%) |
| Prothrombin Time (seconds) with Dade® Innovin® | Ci-Trol 1 | 11.0 | 0.07 | 0.7 | 0.08 | 0.8 |
| | Ci-Trol 2 | 28.8 | 0.22 | 0.8 | 0.33 | 1.2 |
| | Ci-Trol 3 | 46.6 | 0.36 | 0.8 | 0.75 | 1.6 |
| | Plasma pool 1 | 10.3 | 0.07 | 0.6 | 0.09 | 0.9 |
| | Plasma pool 2 | 15.4 | 0.09 | 0.6 | 0.16 | 1.0 |
| | Plasma pool 3 | 19.4 | 0.1 | 0.5 | 0.19 | 1.0 |
| | Plasma pool 4 | 38.6 | 0.09 | 0.2 | 0.46 | 1.2 |
| | Plasma pool 5 | 49.6 | 0.18 | 0.4 | 0.79 | 1.6 |

510(k) Summary

Classified as Confidential

{10}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

| | Precision within-site | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | | Repeatability | | Within-Device/Lab Precision | |
| | | Mean | SD [assay unit] | CV (%) | SD [assay unit] | Within Device/Lab CV (%) |
| | Plasma pool 6 | 68.5 | 0.27 | 0.4 | 1.2 | 1.8 |
| Prothrombin Time (INR) with Dade® Innovin® | Ci-Trol 1 | 1.03 | 0.007 | 0.7 | 0.008 | 0.8 |
| | Ci-Trol 2 | 2.91 | 0.025 | 0.9 | 0.037 | 1.3 |
| | Ci-Trol 3 | 4.90 | 0.042 | 0.9 | 0.085 | 1.7 |
| | Plasma pool 1 | 1.01 | 0.005 | 0.5 | 0.009 | 0.9 |
| | Plasma pool 2 | 2.28 | 0.011 | 0.5 | 0.027 | 1.2 |
| | Plasma pool 3 | 3.18 | 0.011 | 0.4 | 0.041 | 1.3 |
| | Plasma pool 4 | 5.11 | 0.021 | 0.4 | 0.096 | 1.9 |
| | Plasma pool 5 | 7.41 | 0.042 | 0.6 | 0.162 | 2.2 |
| Activated Partial Thromboplastin Time (APTT) (seconds) with Dade® Actin® FSL Activated PTT Reagent | Ci-Trol 1 | 26.6 | 0.11 | 0.4 | 0.2 | 0.7 |
| | Ci-Trol 2 | 49.2 | 0.24 | 0.5 | 0.45 | 0.9 |
| | Ci-Trol 3 | 61.2 | 0.39 | 0.6 | 0.74 | 1.2 |
| | Plasma pool 1 | 27.9 | 0.08 | 0.3 | 0.18 | 0.6 |
| | Plasma pool 2 | 44.4 | 0.29 | 0.7 | 1.15 | 2.6 |
| | Plasma pool 3 | 88.8 | 0.33 | 0.4 | 0.63 | 0.7 |
| | Plasma pool 4 | 122.3 | 1.06 | 0.9 | 1.64 | 1.3 |
| Fibrinogen (mg/dL) with Dade® Thrombin Reagent | Ci-Trol 1 | 267 | 5.4 | 2.0 | 6.3 | 2.4 |
| | Data-Fi Abnormal Fibrinogen Control | 101 | 3.2 | 3.2 | 3.4 | 3.3 |
| | Control Plasma N | 238 | 5.6 | 2.4 | 5.9 | 2.5 |
| | Control Plasma P | 82 | 5 | 6.1 | 5.1 | 6.2 |
| | Plasma pool 1 | 62 | 0.6 | 1.0 | 0.9 | 1.4 |
| | Plasma pool 2 | 220 | 3 | 1.4 | 4.2 | 1.9 |
| | Plasma pool 3 | 412 | 4.3 | 1.0 | 7.6 | 1.9 |
| | Plasma pool 4 | 747 | 7.8 | 1.0 | 14.5 | 1.9 |
| Antithrombin (%) with INNOVANCE® Antithrombin | Control Plasma N | 93.5 | 1.28 | 1.4 | 1.45 | 1.6 |
| | Control Plasma P | 31.5 | 0.66 | 2.1 | 0.77 | 2.5 |
| | Plasma pool 1 | 17.5 | 0.78 | 4.5 | 0.9 | 5.2 |

510(k) Summary
Page 7 of 13

Classified as Confidential

{11}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

| | Precision within-site | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | | Repeatability | | Within-Device/Lab Precision | |
| | | Mean | SD [assay unit] | CV (%) | SD [assay unit] | Within Device/Lab CV (%) |
| | Plasma pool 2 | 40.9 | 0.78 | 1.9 | 0.79 | 1.9 |
| | Plasma pool 3 | 104.0 | 0.95 | 0.9 | 1.85 | 1.8 |
| | Plasma pool 4 | 116.3 | 1.41 | 1.2 | 1.91 | 1.6 |
| D-Dimer (mg/L FEU) with INNOVANCE® D-Dimer | INNOVANCE D-Dimer Control 1 | 0.27 | 0.007 | 2.6 | 0.009 | 3.4 |
| | INNOVANCE D-Dimer Control 2 | 2.46 | 0.046 | 1.9 | 0.078 | 3.2 |
| | Plasma pool 1 | 0.19 | 0.008 | 4.2 | 0.011 | 5.8 |
| | Plasma pool 2 | 0.48 | 0.013 | 2.8 | 0.022 | 4.5 |
| | Plasma pool 3 | 2.46 | 0.042 | 1.7 | 0.08 | 3.3 |
| | Plasma pool 4 | 28.62 | 0.524 | 1.8 | 0.919 | 3.2 |

Linearity &amp; Measuring Range:
Linearity studies were performed for the following calibrated assays on the CN-series (CN-6000) coagulation analyzer: Fibrinogen with Dade® Thrombin Reagent, Antithrombin with INNOVANCE® Antithrombin, and D-dimer with INNOVANCE® D-Dimer. All reagents met the predetermined acceptance criteria and supported the Analytical Measuring Interval (AMI) claim. Studies were conducted as described in CLSI EP06 2nd Edition.

| Application | Measured Linear Range | Analytical Measurement Interval |
| --- | --- | --- |
| Prothrombin Time (seconds) with Dade® Innovin® | Not applicable | 8.7 – 90.0 seconds |
| Prothrombin Time (INR) with Dade® Innovin® | Not applicable | 0.93 – 8.00 INR |
| Activated Partial Thromboplastin Time (seconds) with Dade® Actin® FSL | Not applicable | 20.0 – 139.0 seconds |
| Fibrinogen with Dade® Thrombin Reagent | 38.4 – 900.2 mg/dL | 50 – 860 mg/dL |
| Antithrombin with INNOVANCE® Antithrombin | 7.56 – 130.42 % of norm. | 9.0 – 128.0 % of norm. |
| D-dimer with INNOVANCE® D-Dimer | 0.180 – 35.836 mg/L FEU | 0.19 – 35.20 mg/L FEU |

510(k) Summary
Classified as Confidential

{12}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

Interference Studies:
The interference study was performed on the CN-series (CN-6000) analyzer. The study was conducted with one reagent lot and five replicates per sample. All pre-established criteria were met, and the study demonstrated the proposed device has substantially equivalent optical performance related to hemolytic, icteric, lipemic, and Hydroxyethyl Starch (HES) potential interference in samples.

| Reagent | Base pool | High Level without Interference | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | Hemoglobin | Conjugated Bilirubin | Unconjugated Bilirubin | Triglycerides | HES |
| Dade® Innovin® (seconds) | Normal | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 825 mg/dL | - |
| | Pathological (Prolonged) | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 825 mg/dL | - |
| Dade® Innovin® (INR) | Normal | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 825 mg/dL | - |
| | Pathological (High) | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 825 mg/dL | - |
| Dade® Actin® FSL Activated PTT Reagent | Normal | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 825 mg/dL | - |
| | Pathological (Prolonged) | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 825 mg/dL | - |
| Dade® Thrombin Reagent | Pathological (Low) | 150 mg/dL | 20 mg/dL | 15 mg/dL | 605 mg/dL | 25.9 g/L |
| | Normal | 561 mg/dL | 44 mg/dL | 66 mg/dL | 605 mg/dL | 31.4 g/L |
| | Pathological (High) | 561 mg/dL | 44 mg/dL | 66 mg/dL | 605 mg/dL | 31.4 g/L |
| INNOVANCE® Antithrombin | Pathological (Low) | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 495 mg/dL | - |
| | Normal | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 495 mg/dL | - |
| INNOVANCE® D-Dimer | Normal (Low) | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 715 mg/dL | - |
| | Normal | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 715 mg/dL | - |
| | Pathological (High) | 1100 mg/dL | 44 mg/dL | 66 mg/dL | 715 mg/dL | - |

Reagent Carryover:
This study has been designed in accordance with CLSI guidelines H57-A and EP10-A3-AMD. Two reagent lots were analyzed on the CN-series (CN-6000) analyzer. All results met the specified criteria, and the study showed that there was no reagent carryover effects from one application to another on the Automated Blood Coagulation Analyzer CN-6000.

Sample Carryover:
The sample carryover study evaluated the effects of possible contamination from one sample to the other and confirmed that the aspiration and washing of the sample probe on the CN series (CN-6000) reduces the likelihood of carryover contamination to negligible levels. The results of the sample carryover study met all specified criteria for PT, APTT, Fibrinogen, Antithrombin, and D-dimer quantitation assays.

510(k) Summary
Classified as Confidential

{13}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

# Limit of Blank/Detection/Quantitation

The Limit of Blank study was designed in accordance with CLSI guideline EP17-A2 and CLSI guideline EP39-ED1. The studies were carried out on one analyzer with three calibrated assays, two different reagent lots, five replicates per run per day over three days for a total of 15 measurements per analyte-free (LOB) and low analyte (LOD/LOQ) samples.

| Application | Measured LoB and LoD | Measured LoQ |
| --- | --- | --- |
| Fibrinogen with Dade® Thrombin Reagent | Not applicable | LoQ – 36.1 mg/dL |
| Antithrombin with INNOVANCE® Antithrombin | LoB – 2.21% of norm.
LoD – 2.95% of norm. | LoQ – 8.31% of norm. |
| D-Dimer with INNOVANCE® D-Dimer | LoB – 0.085 mg/L FEU
LoD – 0.101 mg/L FEU | 0.182 mg/L FEU |

# Factor Sensitivity (PT, APTT):

The factor sensitivity study was conducted in accordance with CLSI guideline H47 Ed3. Reagent sensitivity to factors V and VII was performed using two lots of Dade® Innovin®, and reagent sensitivity to factors VIII and IX was performed using two lots of Dade® Actin® FSL. The calculated factor sensitivity results were as follows:

Factor V: 40.8% - 44.5%
Factor VII: 45.8% - 48.3%
Factor VIII: 40.2% - 42.8%
Factor IX: 33.2%

# Heparin Sensitivity (APTT):

A Heparin sensitivity study was conducted for APTT assay to assess instrument performance. Samples from patients receiving unfractionated heparin (UFH) therapy were measured with both the CN-6000 and CS-5100 coagulation analyzers using two APTT reagent lots. Passing-Bablok analysis for two lots yielded the following correlation.

- Lot 1: n = 56, y = 1.000x - 0.200, r = 0.9993
- Lot 2: n = 56, y = 0.981x - 0.313, r = 0.9995

# Lupus Anticoagulant (LA) Sensitivity Study:

The LA sensitivity study was performed in-house evaluating 2 lots of Dade® Actin® FSL reagent on a total of 24 LA positive samples. The results for the study met the specified criteria.

510(k) Summary
Classified as Confidential

{14}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

## Stability:

### Reagents &amp; Buffer Stability
Reagent stability was assessed for Dade® Innovin®, Dade® Actin® FSL, Dade® Thrombin, INNOVANCE® Antithrombin, INNOVANCE® D-Dimer, and Dade® Owren’s Veronal Buffer. The manufacturer’s claim for onboard stability for all reagents was met.

### QC Stability
Studies were designed in accordance with CLSI guideline EP25. The manufacturer’s claim for onboard stability for all QC materials was met.

### High Dose Hook Effect
This study was designed in accordance with CLSI guideline EP34-ED1. The study was conducted with one reagent lot on one analyzer. The delta Optical Density, dOD, of each measurement, the presence of the antigen excess flag, and whether the instrument performed an automatic redilution (samples measuring 4.4mg/L FEU or less) were recorded for each sample.

The pre-established acceptance criterion of appropriate instrument flagging with “antigen excess”, and no likelihood of reporting an erroneously low result due to High Dose Hook effect up to 500 mg/L FEU was confirmed. Therefore, the acceptance criterion was met for this study.

## Matrix Comparison (Bridging Studies):

### Auto-Dilution vs Manual Dilution:
The Auto-Dilution versus Manual dilution study performed on the CN-Series (CN-6000). Testing was performed for fibrinogen with Dade® Thrombin Reagent and D-Dimer with INNOVANCE® D-Dimer. A minimum of three samples per assay were tested, with five replicates per sample over three days. The pre-defined acceptance criteria were met for this study.

### Uncapped Specimens vs Capped Specimens:
The objective of the uncapped versus capped specimens study was to determine equivalence of Prothrombin time (PT) with Dade® INNOVIN®, Activated partial thromboplastin time (APTT) with Dade® Actin® FSL, Fibrinogen with Dade® Thrombin Reagent, Antithrombin (AT) with INNOVANCE® Antithrombin and D-Dimer with INNOVANCE® D-Dimer results obtained from open (i.e., uncapped) blood collection tube samples versus closed (i.e., capped) blood collection tube samples. The pre-defined acceptance criteria were met.

### Frozen Specimens vs Fresh Specimens:
The objective of the frozen versus fresh specimens study was to determine equivalency of

510(k) Summary
Page 11 of 13
Classified as Confidential

{15}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

Prothrombin time (PT) with Dade® INNOVIN®, Activated partial thromboplastin time (APTT) with Dade® Actin® FSL, Fibrinogen with Dade® Thrombin Reagent, Antithrombin (AT) with INNOVANCE® Antithrombin and D-Dimer with INNOVANCE® D-Dimer results obtained from frozen human citrated plasma versus fresh human citrated plasma on the CN-6000 analyzer. The results for this study were determined to be acceptable.

## Micro Mode vs Normal Mode Analysis:

The objective of the micro mode analysis versus normal mode analysis study was to assess comparability of Prothrombin time (PT) with Dade® INNOVIN®, Activated partial thromboplastin time (APTT) with Dade® Actin® FSL, Fibrinogen with Dade® Thrombin Reagent, Antithrombin (AT) with INNOVANCE® Antithrombin and D-Dimer with INNOVANCE® D-Dimer results measured in the micro mode and normal mode sample processing on the CN-6000 analyzer. The pre-established acceptance criteria were met.

## Reference Range:

The Reference Interval study was designed to establish the normal reference ranges on the CN-Series (CN-6000) analyzer for the adult population using Dade® Innovin®, Dade® Actin® FSL, Dade® Thrombin, INNOVANCE® Antithrombin, and INNOVANCE® D-Dimer reagents. The study was conducted at three external clinical sites within the United States using adult samples.

| Assay | Reference Interval |
| --- | --- |
| | Sysmex® CN-6000 |
| Prothrombin Time (seconds) using Dade® Innovin | 2.5^{th} – 97.5^{th}
9.9 – 12.3 (sec) |
| Prothrombin Time (INR) using Dade® Innovin | 2.5^{th} – 97.5^{th}
0.93 – 1.16 (INR) |
| Activated Partial Thromboplastin Time using Dade® Actin® FSL | 2.5^{th} – 97.5^{th}
23.8 – 32.0 (sec) |
| Fibrinogen quantitation using Dade® Thrombin Reagent | 2.5^{th} – 97.5^{th}
192 – 440 (mg/dL) |
| Antithrombin quantitation using Dade® Thrombin Reagent | 2.5^{th} – 97.5^{th}
83.7 – 121.6 (%) |
| D-Dimer quantitation using INNOVANCE® D-Dimer | minimum – 97.5^{th}
< 0.19 – 1.27 (mg/L FEU) |

## Conclusion:

The CN-series (CN-6000) is similar to the CS-5100 in its intended use and system technological characteristics. There are minor differences in the number of probes, light source for the CN-series, rinse &amp; buffer cleaning solutions, reagent cooling temperature and number of sample racks.

The list of assays used with the CN-series is the same as with the previously cleared assays in the CS-5100 (K150678).

510(k) Summary
Page 12 of 13
Classified as Confidential

{16}

Sysmex America, Inc.
CN-Series (CN-6000) Automated Blood Coagulation Analyzer
Premarket Notification

The technological characteristics and operating principles of the CN-series are essentially the same as the predicate CS-5100. In addition, performance testing did not raise any issues with safety and effectiveness of the CN-series when compared with the CS-5100 instrument.

The data from the analytical and clinical testing supports that the CN-series (CN-6000) instrument is substantially equivalent to the previously cleared CS-5100 instrument (K150678), and the device is safe and effective for its intended use.

510(k) Summary
Page 13 of 13
Classified as Confidential